Sector News

Medtronic seeks EU approval for $43 billion Covidien deal

October 14, 2014
Life sciences
(Reuters) – U.S. medical equipment maker Medtronic (MDT.N) has asked European Union antitrust regulators to approve its proposed $43 billion (26.73 billion pounds) purchase of Irish peer Covidien Plc (COV.N), the European Commission said on Monday.
 
The acquisition, which will put Medtronic on about the same footing as industry leader Johnson & Johnson (JNJ.N), will reduce its overall global tax burden.
 
Medtronic however said it is not an inversion deal where U.S. companies acquire foreign rivals to move their tax domicile abroad, but rather a move to boost its medical technology strategy.
 
The EU competition authority has set a Nov. 14 deadline for its decision. It can either clear the deal unconditionally or ask for concessions to allay possible antitrust concerns or open an in-depth investigation.
 
Analysts said the disparate businesses of the two companies should not trigger any significant regulatory worries.
 
(Reporting by Foo Yun Chee; editing by Susan Thomas)

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend